Current Affairs Security

Unitree's IPO Derivatives Bubble: How Hyperliquid Traders Built a $38 Billion House of Cards

2026-08-16

Crypto traders are doing what they do best: pricing the moon before the rocket launches. Unitree Robotics hits Shanghai's STAR Market soon—priced at roughly $9 billion, IPO price of 150.80 yuan per share. Reasonable enough. Hyperliquid traders, meanwhile, are pricing the stock at $93 a share. That's $38 billion. More than four times higher. The gap between derivatives and reality is so enormous it's practically begging for a disaster.

Pre-IPO perpetuals let you speculate on a private company's eventual public price without owning actual shares. Perfect for leverage addicts. Hyperliquid contracts were trading between $92 and $94 on Friday, betting that Unitree will be worth nearly 30 grand per share when it debuts between 17 and 21 August 2026. Fair play if you believe in the story. Revenue hit $253 million last year, up 335%. They shipped 5,500 humanoid robots. The offering was oversubscribed by retail investors more than 8,000 times. Excitement? Genuine. Pricing in the derivatives market? Unhinged.

Allium analysts worked the numbers. Unitree could open at twice the IPO price—a proper moonshot from any rational perspective—and still liquidate roughly a third of long positions held by bullish traders. At $45 per share, you're still 52% below what derivatives players are betting on. But that's close enough to margin calls to trigger a cascade of forced selling. Welcome to the liquidation cascade. This is where leverage eats itself.

Hyperliquid itself is the platform worth watching here. It rose to prominence as an onchain venue for perpetual futures—derivatives with no expiration date, leveraged positions that live forever until something breaks them. The platform has expanded aggressively beyond crypto into commodities and now pre-IPO stocks. Pre-IPO perpetuals for Unitree and Moonshot AI joined a TradFi lineup that now exceeds 200 products. Sometimes these bets are shockingly accurate—a pre-IPO contract tracking CXMT, the Chinese memory-chip maker, came within 2.5% of its Shanghai opening price in July. Sometimes they're catastrophically wrong.

The problem is structural. Pre-IPO valuations have no public market to establish a consensus. There's no order book, no price discovery, no crowd of rational actors arguing it out. Add 10x leverage to an instrument tracking an opaque private valuation, and you've essentially built a machine for outsized losses. The smaller traders on Hyperliquid already smell the danger. Bets below $50,000 are 70% short by value. The big money? Nearly balanced at $6.5 million long and $6.6 million short. But retail is hedging.

At IPO price, Unitree trades at 219 times 2025 earnings and 36 times sales. That's already aggressive. Q1 2025 revenue rose 68.5% to 422.8 million yuan, but profits excluding one-off items fell 52.6% to 40.3 million yuan. Spending on research and marketing is eating margins. The humanoid robotics market might scale. Or it might not. Either way, the derivatives market is pricing conviction that public investors don't actually have. Not yet. The gap between $9 billion and $38 billion leaves almost no room for disappointment once real trading starts.

Source & further reading:

Sources